Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

NCT02503345 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperoxaluria
Nephrolithiasis
Kidney Stones
Hyperoxaluria
Dietary Hyperoxaluria

Interventions

DRUG: ALLN-177 low dose
DRUG: ALLN-177 mid dose
DRUG: ALLN-177 high dose
DRUG: Placebo

Sponsor

Allena Pharmaceuticals